Emerging studies suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , could provide a significant step forward for obesity treatment. Initial patient trials have demonstrated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide